Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Jan;19(1):21–27. doi: 10.1111/j.1365-2125.1985.tb02608.x

The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.

J N Harvey, D P Worth, J Brown, M R Lee
PMCID: PMC1463787  PMID: 2858215

Abstract

The effect of a single oral dose of 100 mg of fenoldopam on renal function and blood pressure was investigated in seven healthy male subjects in a double-blind placebo controlled study. Mean diastolic blood pressure fell by 10 mm Hg, 45 min after oral dosing and then gradually returned to baseline values. There was an increase in pulse rate and a delayed rise in systolic blood pressure. Measured from 30 to 120 min after drug ingestion, mean effective renal plasma flow increased to 158% of the value observed after placebo; mean glomerular filtration rate rose to 109% of the placebo value. Measured from 120 to 210 min after administration of the drug, effective renal plasma flow and glomerular filtration rate had returned to baseline values. Fenoldopam produced a small increase in the mean sodium excretion rate which was not significantly different from the fall after placebo. No change was detected in urine flow or potassium excretion rate. Mean plasma renin activity increased three-fold 1 h after oral dosing. Plasma aldosterone did not show a parallel increase although the plasma concentration at 1 h was significantly higher than after placebo. The results show a pronounced renal vasodilator effect lasting about 2 h. The findings are consistent with marked DA1 receptor agonist activity.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman D. M., Blumberg A. L., McCafferty J. P., Sherman S. S., Weinstock J., Kaiser C., Berkowitz B. Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526. Fed Proc. 1983 Feb;42(2):186–190. [PubMed] [Google Scholar]
  2. Bell C., Lang W. J., Laska F. Dopamine-containing vasomotor nerves in the dog kidney. J Neurochem. 1978 Jul;31(1):77–83. doi: 10.1111/j.1471-4159.1978.tb12435.x. [DOI] [PubMed] [Google Scholar]
  3. Brunner H. R., Jaeger P., Ferguson R. K., Jequier E., Turini G., Gavras H. Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J. 1978 Aug 5;2(6134):385–388. doi: 10.1136/bmj.2.6134.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campbell D. J., Mendelsohn F. A., Adam W. R., Funder J. W. Is aldosterone secretion under dopaminergic control? Circ Res. 1981 Dec;49(6):1217–1227. doi: 10.1161/01.res.49.6.1217. [DOI] [PubMed] [Google Scholar]
  5. Casson I. F., Lee M. R., Brownjohn A. M., Parsons F. M., Davison A. M., Will E. J., Clayden A. D. Failure of renal dopamine response to salt loading in chronic renal disease. Br Med J (Clin Res Ed) 1983 Feb 12;286(6364):503–506. doi: 10.1136/bmj.286.6364.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dinerstein R. J., Vannice J., Henderson R. C., Roth L. J., Goldberg L. I., Hoffmann P. C. Histofluorescence techniques provide evidence for dopamine-containing neuronal elements in canine kidney. Science. 1979 Aug 3;205(4405):497–499. doi: 10.1126/science.451614. [DOI] [PubMed] [Google Scholar]
  7. EBLE J. N. A PROPOSED MECHANISM FOR THE DEPRESSOR EFFECT OF DOPAMINE IN THE ANESTHETIZED DOG. J Pharmacol Exp Ther. 1964 Jul;145:64–70. [PubMed] [Google Scholar]
  8. Goldberg L. I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972 Mar;24(1):1–29. [PubMed] [Google Scholar]
  9. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  10. Hahn R. A., Wardell J. R., Jr, Sarau H. M., Ridley P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther. 1982 Nov;223(2):305–313. [PubMed] [Google Scholar]
  11. Harries J. D., Mildenberger R. R., Malowany A. S., Drummond K. N. A computerized cummulative integral method for the precise measurement of the glomerular filtration rate. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1148–1155. doi: 10.3181/00379727-140-36630. [DOI] [PubMed] [Google Scholar]
  12. Harvey J. N., Casson I. F., Clayden A. D., Cope G. F., Perkins C. M., Lee M. R. A paradoxical fall in urine dopamine output when patients with essential hypertension are given added dietary salt. Clin Sci (Lond) 1984 Jul;67(1):83–88. doi: 10.1042/cs0670083. [DOI] [PubMed] [Google Scholar]
  13. Imbs J. L., Schmidt M., Schwartz J. Effect of dopamine on renin secretion in the anesthetized dog. Eur J Pharmacol. 1975 Aug;33(1):151–157. doi: 10.1016/0014-2999(75)90150-8. [DOI] [PubMed] [Google Scholar]
  14. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 1979 Jan 11;277(5692):93–96. doi: 10.1038/277093a0. [DOI] [PubMed] [Google Scholar]
  15. Lang W. J., Bell C., Conway E. L., Padanyi R. Cutaneous and muscular rasodilation in the canine hindlimb evoked by central stimulation. Circ Res. 1976 Jun;38(6):560–566. doi: 10.1161/01.res.38.6.560. [DOI] [PubMed] [Google Scholar]
  16. MCDONALD R. H., Jr, GOLDBERG L. I., MCNAY J. L., TUTTLE E. P., Jr EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW. J Clin Invest. 1964 Jun;43:1116–1124. doi: 10.1172/JCI104996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Noth R. H., McCallum R. W., Contino C., Havelick J. Tonic dopaminergic suppression of plasma aldosterone. J Clin Endocrinol Metab. 1980 Jul;51(1):64–69. doi: 10.1210/jcem-51-1-64. [DOI] [PubMed] [Google Scholar]
  18. Perkins C. M., Casson I. F., Cope G. F., Lee M. R. Failure of salt to mobilise renal dopamine in essential hypertension. Lancet. 1980 Dec 20;2(8208-8209):1370–1370. doi: 10.1016/S0140-6736(80)92432-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sowers J. R., Barrett J. D., Sambhi M. P. Dopaminergic modulation of renin release. Clin Exp Hypertens. 1981;3(1):15–25. doi: 10.3109/10641968109037165. [DOI] [PubMed] [Google Scholar]
  20. Stote R. M., Dubb J. W., Familiar R. G., Erb B. B., Alexander F. A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther. 1983 Sep;34(3):309–315. doi: 10.1038/clpt.1983.173. [DOI] [PubMed] [Google Scholar]
  21. Ueda H., Kaneko Y., Takeda T., Ikeda T., Yagi S. Observation on the mechanism of renin release by hydralazine in hypertensive patients. Circ Res. 1970 Oct;27(Suppl):201–206. [PubMed] [Google Scholar]
  22. Yeh B. K., McNay J. L., Goldberg L. I. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther. 1969 Aug;168(2):303–309. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES